165 related articles for article (PubMed ID: 34153143)
1. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.
Mühlbacher J; Schörgenhofer C; Doberer K; Dürr M; Budde K; Eskandary F; Mayer KA; Schranz S; Ely S; Reiter B; Chong E; Adler SH; Jilma B; Böhmig GA
Transpl Int; 2021 Aug; 34(8):1542-1552. PubMed ID: 34153143
[TBL] [Abstract][Full Text] [Related]
2. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K; Duerr M; Halloran PF; Eskandary F; Budde K; Regele H; Reeve J; Borski A; Kozakowski N; Reindl-Schwaighofer R; Waiser J; Lachmann N; Schranz S; Firbas C; Mühlbacher J; Gelbenegger G; Perkmann T; Wahrmann M; Kainz A; Ristl R; Halleck F; Bond G; Chong E; Jilma B; Böhmig GA
J Am Soc Nephrol; 2021 Mar; 32(3):708-722. PubMed ID: 33443079
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena.
Borski A; Eskandary F; Haindl S; Doberer K; Mühlbacher J; Mayer KA; Budde K; Halloran PF; Chong E; Jilma B; Böhmig GA; Wahrmann M
Transplantation; 2023 Feb; 107(2):495-503. PubMed ID: 35969004
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10.
Mayer KA; Doberer K; Halloran PF; Budde K; Haindl S; Mühlbacher J; Eskandary F; Viard T; Casas S; Jilma B; Böhmig GA
Transplant Direct; 2022 Dec; 8(12):e1406. PubMed ID: 36382130
[TBL] [Abstract][Full Text] [Related]
6. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
[TBL] [Abstract][Full Text] [Related]
7. A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.
Jannot AS; Vuillemin X; Etienne I; Buchler M; Hurault de Ligny B; Choukroun G; Colosio C; Thierry A; Vigneau C; Moulin B; Rerolle JP; Heng AE; Subra JF; Legendre C; Beaune P; Loriot MA; Thervet E; Pallet N
Ther Drug Monit; 2016 Apr; 38(2):223-9. PubMed ID: 26829596
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
9. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.
Lytton SD; Berg U; Nemeth A; Ingelman-Sundberg M
Clin Exp Immunol; 2002 Feb; 127(2):293-302. PubMed ID: 11876753
[TBL] [Abstract][Full Text] [Related]
11. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
Mease PJ; Gottlieb AB; Berman A; Drescher E; Xing J; Wong R; Banerjee S
Arthritis Rheumatol; 2016 Sep; 68(9):2163-73. PubMed ID: 27059799
[TBL] [Abstract][Full Text] [Related]
13. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
14. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
Gómez-Bravo MA; Apellaniz-Ruiz M; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Bilbao I; Alamo JM; Millán O; Brunet M; Rodríguez-Antona C
Pharmacogenet Genomics; 2018 Feb; 28(2):41-48. PubMed ID: 29256966
[TBL] [Abstract][Full Text] [Related]
15. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.
Jordan SC; Ammerman N; Choi J; Huang E; Najjar R; Peng A; Sethi S; Sandhu R; Atienza J; Toyoda M; Ge S; Lim K; Gillespie M; Zhang X; Haas M; Vo A
Kidney Int Rep; 2022 Apr; 7(4):720-731. PubMed ID: 35497778
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Mayer KA; Budde K; Halloran PF; Doberer K; Rostaing L; Eskandary F; Christamentl A; Wahrmann M; Regele H; Schranz S; Ely S; Firbas C; Schörgenhofer C; Kainz A; Loupy A; Härtle S; Boxhammer R; Jilma B; Böhmig GA
Trials; 2022 Apr; 23(1):270. PubMed ID: 35395951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
